Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations.
Mutations in the two breast cancer susceptibility genes BRCA1 and BRCA2 are associated with increased risk of breast and ovarian cancer. Patients with mutations in both genes are rarely reported and often involve Ashkenazi founder mutations. Here we report the first identification of a Danish breast and ovarian cancer family heterozygote for mutations in the BRCA1 and BRCA2 genes. The BRCA1 nucleotide 5215G > A/c.5096G > A mutation results in the missense mutation Arg1699Gln, while the BRCA2 nucleotide 859 + 4A > G/c.631 + 4A > G is novel. Exon trapping experiments and reverse transcriptase (RT)-PCR analysis revealed that the BRCA2 mutation results in skipping of exon 7, thereby introducing a frameshift and a premature stop codon. We therefore classify the mutation as disease causing. Since the BRCA1 Arg1699Gln mutation is also suggested to be disease-causing, we consider this family double heterozygote for BRCA1 and BRCA2 mutations.
Steffensen
Ane Y
AY
Department of Clinical Biochemistry 4111, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.
Jønson
Lars
L
Ejlertsen
Bent
B
Gerdes
Anne-Marie
AM
Nielsen
Finn C
FC
Hansen
Thomas V O
TV
D001483:Base Sequence; D001943:Breast Neoplasms / Q000235:genetics*; D018567:Breast Neoplasms, Male / Q000235:genetics; D003718:Denmark; D005190:Family; D005260:Female; D016368:Frameshift Mutation; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006801:Humans; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009154:Mutation; D020125:Mutation, Missense; D010051:Ovarian Neoplasms / Q000235:genetics*; D010375:Pedigree; D020133:Reverse Transcriptase Polymerase Chain Reaction
J Med Genet. 2002 Aug;39(8):e44
12161611
Breast Cancer Res Treat. 2009 May;115(1):69-76
18500671
Nucleic Acids Res. 2003 Jul 1;31(13):3812-4
12824425
J Clin Oncol. 2002 Mar 15;20(6):1480-90
11896095
Cancer Res. 2002 May 15;62(10):2741-3
12019146
Breast Cancer Res Treat. 2009 May;115(2):315-23
18546071
Am J Hum Genet. 1998 Oct;63(4):1224-7
9758598
Nucleic Acids Res. 1996 Sep 1;24(17):3439-52
8811101
Am J Hum Genet. 2004 Oct;75(4):535-44
15290653
Breast Cancer Res. 2009;11(1):R8
19200354
Breast Cancer Res. 2007;9(6):R82
18036263
Biochem Cell Biol. 2005 Dec;83(6):721-7
16333323
Nat Genet. 1996 May;13(1):126-8
8673092
J Comput Biol. 2004;11(2-3):377-94
15285897
Hum Mol Genet. 2001 Feb 15;10(4):353-60
11157798
Bioinformatics. 2005 Jul 15;21(14):3176-8
15879453
Cancer Res. 2006 Feb 15;66(4):2019-27
16489001
J Hum Genet. 2000;45(6):351-7
11185744
BMC Med Genet. 2008 Jul 02;9:58
18597679
Ann Oncol. 2009 May;20(5):874-8
19179552
Breast Cancer Res Treat. 2010 Feb;119(3):547-50
19267246
Fam Cancer. 2006;5(1):89-93
16528612
Nat Genet. 1996 May;13(1):117-9
8673089
Nucleic Acids Res. 2002 Sep 1;30(17):3894-900
12202775
J Med Genet. 2005 Oct;42(10):737-48
16199547
J Comput Biol. 1997 Fall;4(3):311-23
9278062
Acta Oncol. 2008;47(4):772-7
18465347
J Clin Oncol. 2004 May 1;22(9):1638-45
15117986
J Clin Oncol. 2008 Sep 1;26(25):4212-4; author reply 4214-5
18757339
J Med Genet. 2004 Jul;41(7):492-507
15235020
Nat Med. 2001 May;7(5):552-6
11329055
Nat Struct Mol Biol. 2004 Jun;11(6):512-8
15133502
J Med Genet. 2005 Mar;42(3):e20
15744030
Fam Cancer. 2008;7(2):119-24
17636421